Greer A. Burkholder

Greer A. Burkholder

Auto-generated profile, based on publicly available information

Greer A. Burkholder

University of Alabama at Birmingham, Birmingham, AL, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
CMChristina A. Muzny
Christina A. Muzny
GBGreer A. Md Burkholder
Greer A. Md Burkholder
KFKaren R. Msn Fry
Karen R. Msn Fry
EAErika L. Austin
Erika L. Austin
JSJane R. Schwebke
Jane R. Schwebke
Background: Trichomonas vaginalis is the most common nonviral sexually transmitted infection. T. vaginalis nucleic acid amplification testing (NAAT) recently became available at the University of Alabama at Birmingham human immunodeficiency virus (HIV) clinic. The objective of this study was to determine the uptake of T. vaginalis NAAT testing among clinic providers during the first year of test availability in addition to T. vaginalis prevalence and predictors based on NAAT results. Methods: This was a retrospective review of HIV+ women and men ages ≥16 years at the University of Alabama at Birmingham HIV Clinic, including those receiving a T. vaginalis NAAT on a genitourinary specimen. Results: Between August 2014 and August 2015, 3163 HIV+ patients were seen (768 women, 2395 men), of whom 861 (27.3%) received a T. vaginalis NAAT; 402 women (52.3%) and 459 men (19.2%). Among those with T. vaginalis NAAT results, 70 (17.4%) of 402 women and 12 (2.6%) of 459 men (9 men who have sex with women, 1 man who has sex with men, 2 unknown) tested positive. In adjusted analyses for women, age ≤40 years (odds ratio [OR], 2.93; 95% confidence interval [CI], 1.23–6.96), current cocaine use (OR, 4.86; 95% CI, 1.57–15.06), and CD4 < 200 cells/mm3 (OR, 6.09; 95% CI, 1.68–22.11) were significantly associated with increased odds of a positive T. vaginalis NAAT. For those with a positive T. vaginalis NAAT, treatment was prescribed for 65 (92.9%) of 70 women and 10 (83.3%) of 12 men. Conclusions: Initial uptake of T. vaginalis NAAT testing was modest at this HIV clinic yet identified a high prevalence among women tested. Emphasis on the need for testing in HIV+ women is necessary.

22 February 2021 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
HCHarry Choi
Harry Choi
ADAmit K. Dey
Amit K. Dey
GSGaurav Sharma
Gaurav Sharma
RBRahul Bhoite
Rahul Bhoite
GBGreer Burkholder
Greer Burkholder
HJHani Jneid
Hani Jneid

29 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GBGreer A Burkholder
Greer A Burkholder
ATAshutosh R Tamhane
Ashutosh R Tamhane
MSMonika M Safford
Monika M Safford
PMPaul M Muntner
Paul M Muntner
AWAmanda L Willig
Amanda L Willig
MMMichael J Mugavero
Michael J Mugavero
African Americans are disproportionately affected by both HIV and hypertension. Failure to modify risk factors for cardiovascular disease and chronic kidney disease such as hypertension among HIV-infected patients may attenuate the benefits conferred by combination antiretroviral therapy. In the general population, African Americans with hypertension are less likely to have controlled blood pressure than whites. However, racial differences in blood pressure control among HIV-infected patients are not well studied. We conducted a cross-sectional study evaluating racial differences in hypertension prevalence, treatment, and control among 1,664 patients attending the University of Alabama at Birmingham HIV Clinic in 2013. Multivariable analyses were performed to calculate prevalence ratios (PR) with 95% confidence intervals (CI) as the measure of association between race and hypertension prevalence and control while adjusting for other covariates. The mean age of patients was 47 years, 77% were male and 54% African-American. The prevalence of hypertension was higher among African Americans compared with whites (49% vs. 43%; p = 0.02). Among those with hypertension, 91% of African Americans and 93% of whites were treated (p = 0.43). Among those treated, 50% of African Americans versus 60% of whites had controlled blood pressure (systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg) (p = 0.007). After multivariable adjustment for potential confounders, prevalence of hypertension was higher among African Americans compared to whites (PR 1.25; 95% CI 1.12–1.39) and prevalence of BP control was lower (PR 0.80; 95% CI 0.69–0.93). Despite comparable levels of hypertension treatment, African Americans in our HIV cohort were less likely to achieve blood pressure control. This may place them at increased risk for adverse outcomes that disproportionately impact HIV-infected patients, such as cardiovascular disease and chronic kidney disease, and thus attenuate the benefits conferred by combination antiretroviral therapy.

8 October 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
MMMichalina Montaño
Michalina Montaño
ASAdrienne E Shapiro
Adrienne E Shapiro
BWBridget M Whitney
Bridget M Whitney
LBLaura Bamford
Laura Bamford
GBGreer Burkholder
Greer Burkholder
RIRachel A Bender Ignacio
Rachel A Bender Ignacio
Introduction: Since its global reemergence in 2022, monkeypox (mpox) has demonstrated increased incidence and severity among people with human immunodeficiency virus (HIV [PWH]). Predictors of mpox diagnosis, vaccination, and outcomes among PWH are limited. Methods: We included PWH with primary care visits after 1 January 2022 at 9 US sites participating in the Centers for AIDS Research Network of Integrated Clinic Systems Network. We identified mpox diagnosed between 1 June 2022 and 31 May 2023, through a combination of polymerase chain reaction result, diagnosis code, and/or tecovirimat receipt. We examined validated clinical diagnoses, laboratory results, vaccine data, and patient reported outcomes. We evaluated relative risks (RR) of mpox diagnosis, hospitalization, tecovirimat treatment, and vaccine receipt. Findings: Among 19 777 PWH in care, 413 mpox cases (all male sex at birth) occurred (2.2 cases/100 person-years). Age <40 years, geographic region, Hispanic/Latine ethnicity, lack of antiretroviral therapy, detectable HIV viral load, and recent bacterial sexually transmitted infection predicted mpox diagnosis. PWH with CD4 200–349 cells/mm3 were most likely to be hospitalized (adjusted RR, 3.20; 95% confidence interval: 1.44–7.09) compared to CD4 ≥500, but half as likely as those with CD4 <200 to receive tecovirimat. Overall, smallpox/mpox vaccine effectiveness of ≥1 vaccine was 71% (adjusted RR, 0.29; 95% confidence interval: .14–.47) at preventing mpox, and 86% or better with CD4 ≥350 or HIV viral suppression. Non-Hispanic Black PWH were less likely to be vaccinated than other racial/ethnic identities. Interpretation: PWH not on antiretroviral therapy or with unsuppressed HIV were more likely to be diagnosed with, and hospitalized for, mpox. Mpox/smallpox vaccine effectiveness was high, inclusive of those with low CD4 count and HIV viremia.

1 January 2019 in Epidemiology
Verified
Journal Article
Open access
JDJoseph A. Delaney
Joseph A. Delaney
RNRobin M. Nance
Robin M. Nance
BWBridget M. Whitney
Bridget M. Whitney
HCHeidi M. Crane
Heidi M. Crane
JWJessica Williams-Nguyen
Jessica Williams-Nguyen
SHSusan R. Heckbert
Susan R. Heckbert
Background: People living with HIV are at risk of increased myocardial infarction (MI). Cumulative HIV viral load (VL) has been proposed as a better measure of HIV inflammation than other measures of VL, like baseline VL, but its associations with MI are not known. Methods: The multisite Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort includes clinical data and centrally adjudicated MI with distinction between atheroembolic MI (type 1) and MI related to supply–demand mismatch (type 2). We examined CNICS participants who were not on antiretroviral therapy (ART) at enrollment. Cumulative VL (copy-days of virus) from 6 months after enrollment was estimated with a time-weighted sum using the trapezoidal rule. We modeled associations of cumulative and baseline VL with MI by type using marginal structural Cox models. We contrasted the 75% percentile of the VL distribution with the 25% percentile. Results: Among 11,324 participants, 218 MIs occurred between 1996 and 2016. Higher cumulative VL was associated with risk of all MI (hazard ratio [HR] = 1.72; 95% confidence interval [CI] = 1.26, 2.36), type 1 MI (HR = 1.23; 95% CI = 0.78, 1.96), and type 2 MI (HR = 2.52; 95% CI = 1.74, 3.66). While off ART, cumulative VL had a stronger association with type 1 MI (HR = 2.13; 95% CI = 1.15, 3.94) than type 2 MI (HR = 1.25; 95% CI = 0.70, 2.25). Baseline VL was associated with all MI (HR = 1.60; 95% CI = 1.28, 2.01), type 1 MI (HR = 1.73; 95% CI = 1.26, 2.38), and type 2 MI (HR = 1.51; 95% CI = 1.10, 2.08). Conclusions: Higher cumulative and baseline VL is associated with all MI, with a particularly strong association between cumulative VL and type 2 MI.

9 April 2015 in AIDS and Behavior
Verified
Journal Article
Open access
PDF file
LELatesha Elopre
Latesha Elopre
AWAndrew O. Westfall
Andrew O. Westfall
MMMichael J. Mugavero
Michael J. Mugavero
AZAnne Zinski
Anne Zinski
GBGreer Burkholder
Greer Burkholder
NWNicholas Van Wagoner
Nicholas Van Wagoner
Persons receiving effective HIV treatment experience longevity and improvement in quality of life. For those infected, social support is associated with improved medication adherence. Disclosure of infection status is likely a prerequisite for social support. However, little research describes patterns of HIV disclosure by infected persons. We retrospectively evaluated factors associated with disclosure among patients initiating HIV care at a university-based clinic from 2007 to 2012. Of 490 persons initiating care, 13 % had not disclosed their HIV infection to anyone. Black race significantly predicted non-disclosure and persons living with a significant other or friends were more likely to have disclosed their HIV infection versus those living alone. CD4 + T lymphocyte count <200 was associated with nondisclosure and disclosure only to family members. Future research is needed to better understand factors associated with disclosure of HIV infection status, because this could enhance receipt of social support and contribute to improved HIV health outcomes. Las personas que reciben tratamiento para el VIH tienen mejorías en la calidad de vida y sobrevida. Para las personas infectadas, el apoyo social se asocia con una mejor adherencia a la medicación. La divulgación del diagnóstico a familiares o amigos es probablemente un requisito un apoyo social eficaz. Sin embargo, pocos estudios describen los patrones de divulgación del diagnóstico de VIH en personas infectadas. Evaluamos retrospectivamente los factores asociados a la divulgación entre los pacientes que inician cuidado de VIH en un consultorio afiliado a una universidad, entre el 2007 y 2012. De 490 personas que iniciaron el cuidado de VIH, el 13 % no había revelado su diagnóstico a nadie. El ser de raza negra predijo significativamente la no divulgación, y aquellos que Vivian con su pareja o amigos tuvieron más probabilidades de haber revelado su diagnóstico en comparación con los que vivían solos. El recuento de CD4 < 200 estuvo asociado a la no divulgación del diagnóstico y la revelación sólo a miembros de la familia. Se necesitara hacer más estudios en el futuro para comprender mejor los factores asociados a la divulgación del diagnóstico de infección por VIH, ya que esto podría mejorar las posibilidades de apoyo social y contribuir a mejorar la salud de pacientes con VIH.